Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anemia 2Pancreatic Neoplasms 1Neoplasms 1Lymphoproliferative Disorders 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1Cancer Anaemia 1Aortic Aneurysm 1Anemia, Iron-Deficiency 1Advanced Gastric Carcinoma 1

Interventions

Cyclophosphamide 10Radiotherapy 6Epirubicin 6Paclitaxel 5Docetaxel 5Trastuzumab 4Fluorouracil 4Doxorubicin 4Tamoxifen 3Neoadjuvant Therapy 3pertuzumab 2Surgical Procedures, Operative 2Filgrastim 2ferric carboxymaltose 1Thiotepa 1Taxes 1Razoxane 1Radiation 1Prochlorperazine 1Peripheral Blood Stem Cell Transplantation 1Palonosetron 1Microarray Analysis 1Methotrexate 1Injections, Subcutaneous 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Dexrazoxane 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Inflammatory Breast Neoplasms × ferric carboxymaltose × Clear all
NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡